1
|
Avery LB, Wade J, Wang M, Tam A, King A, Piche-Nicholas N, Kavosi MS, Penn S, Cirelli D, Kurz JC, Zhang M, Cunningham O, Jones R, Fennell BJ, McDonnell B, Sakorafas P, Apgar J, Finlay WJ, Lin L, Bloom L, O'Hara DM. Establishing in vitro in vivo correlations to screen monoclonal antibodies for physicochemical properties related to favorable human pharmacokinetics. MAbs 2018; 10:244-255. [PMID: 29271699 DOI: 10.1080/19420862.2017.1417718] [Citation(s) in RCA: 55] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
Implementation of in vitro assays that correlate with in vivo human pharmacokinetics (PK) would provide desirable preclinical tools for the early selection of therapeutic monoclonal antibody (mAb) candidates with minimal non-target-related PK risk. Use of these tools minimizes the likelihood that mAbs with unfavorable PK would be advanced into costly preclinical and clinical development. In total, 42 mAbs varying in isotype and soluble versus membrane targets were tested in in vitro and in vivo studies. MAb physicochemical properties were assessed by measuring non-specific interactions (DNA- and insulin-binding ELISA), self-association (affinity-capture self-interaction nanoparticle spectroscopy) and binding to matrix-immobilized human FcRn (surface plasmon resonance and column chromatography). The range of scores obtained from each in vitro assay trended well with in vivo clearance (CL) using both human FcRn transgenic (Tg32) mouse allometrically projected human CL and observed human CL, where mAbs with high in vitro scores resulted in rapid CL in vivo. Establishing a threshold value for mAb CL in human of 0.32 mL/hr/kg enabled refinement of thresholds for each in vitro assay parameter, and using a combinatorial triage approach enabled the successful differentiation of mAbs at high risk for rapid CL (unfavorable PK) from those with low risk (favorable PK), which allowed mAbs requiring further characterization to be identified. Correlating in vitro parameters with in vivo human CL resulted in a set of in vitro tools for use in early testing that would enable selection of mAbs with the greatest likelihood of success in the clinic, allowing costly late-stage failures related to an inadequate exposure profile, toxicity or lack of efficacy to be avoided.
Collapse
Affiliation(s)
| | - Jason Wade
- b BioMedicine Design, Pfizer Inc. , Cambridge , MA , USA
| | - Mengmeng Wang
- a BioMedicine Design, Pfizer Inc. , Andover , MA , USA
| | - Amy Tam
- b BioMedicine Design, Pfizer Inc. , Cambridge , MA , USA
| | - Amy King
- b BioMedicine Design, Pfizer Inc. , Cambridge , MA , USA
| | | | | | - Steve Penn
- a BioMedicine Design, Pfizer Inc. , Andover , MA , USA.,c Medicine Design, Pfizer Inc. , Cambridge , MA , USA
| | - David Cirelli
- d Pharmaceutical Sciences, Pfizer Inc. , Andover , MA , USA
| | | | - Minlei Zhang
- a BioMedicine Design, Pfizer Inc. , Andover , MA , USA
| | | | - Rhys Jones
- b BioMedicine Design, Pfizer Inc. , Cambridge , MA , USA.,f Currently Medicine Design, Pfizer Inc. , La Jolla , CA , USA
| | | | | | - Paul Sakorafas
- d Pharmaceutical Sciences, Pfizer Inc. , Andover , MA , USA
| | - James Apgar
- b BioMedicine Design, Pfizer Inc. , Cambridge , MA , USA
| | - William J Finlay
- e Biomedicine Design, Pfizer Inc. , Dublin , Ireland.,g Currently CodeBase , Edinburgh , UK
| | - Laura Lin
- b BioMedicine Design, Pfizer Inc. , Cambridge , MA , USA
| | - Laird Bloom
- b BioMedicine Design, Pfizer Inc. , Cambridge , MA , USA
| | | |
Collapse
|
2
|
Avery LB, Wang M, Kavosi MS, Joyce A, Kurz JC, Fan YY, Dowty ME, Zhang M, Zhang Y, Cheng A, Hua F, Jones HM, Neubert H, Polzer RJ, O'Hara DM. Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies. MAbs 2016; 8:1064-78. [PMID: 27232760 DOI: 10.1080/19420862.2016.1193660] [Citation(s) in RCA: 62] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
Abstract
Therapeutic antibodies continue to develop as an emerging drug class, with a need for preclinical tools to better predict in vivo characteristics. Transgenic mice expressing human neonatal Fc receptor (hFcRn) have potential as a preclinical pharmacokinetic (PK) model to project human PK of monoclonal antibodies (mAbs). Using a panel of 27 mAbs with a broad PK range, we sought to characterize and establish utility of this preclinical animal model and provide guidance for its application in drug development of mAbs. This set of mAbs was administered to both hemizygous and homozygous hFcRn transgenic mice (Tg32) at a single intravenous dose, and PK parameters were derived. Higher hFcRn protein tissue expression was confirmed by liquid chromatography-high resolution tandem mass spectrometry in Tg32 homozygous versus hemizygous mice. Clearance (CL) was calculated using non-compartmental analysis and correlations were assessed to historical data in wild-type mouse, non-human primate (NHP), and human. Results show that mAb CL in hFcRn Tg32 homozygous mouse correlate with human (r(2) = 0.83, r = 0.91, p < 0.01) better than NHP (r(2) = 0.67, r = 0.82, p < 0.01) for this dataset. Applying simple allometric scaling using an empirically derived best-fit exponent of 0.93 enabled the prediction of human CL from the Tg32 homozygous mouse within 2-fold error for 100% of mAbs tested. Implementing the Tg32 homozygous mouse model in discovery and preclinical drug development to predict human CL may result in an overall decreased usage of monkeys for PK studies, enhancement of the early selection of lead molecules, and ultimately a decrease in the time for a drug candidate to reach the clinic.
Collapse
Affiliation(s)
- Lindsay B Avery
- a Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc. , Andover , MA , USA
| | - Mengmeng Wang
- a Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc. , Andover , MA , USA
| | - Mania S Kavosi
- a Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc. , Andover , MA , USA
| | - Alison Joyce
- a Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc. , Andover , MA , USA
| | - Jeffrey C Kurz
- a Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc. , Andover , MA , USA
| | - Yao-Yun Fan
- a Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc. , Andover , MA , USA
| | - Martin E Dowty
- a Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc. , Andover , MA , USA
| | - Minlei Zhang
- a Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc. , Andover , MA , USA
| | - Yiqun Zhang
- a Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc. , Andover , MA , USA
| | - Aili Cheng
- b Pharmaceutical Sciences Analytical R&D, Pfizer Inc. , Andover , MA , USA
| | - Fei Hua
- c PharmaTherapeutics Clinical R&D, Pfizer Inc. , Technology Square, Cambridge , MA , USA
| | - Hannah M Jones
- d Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc. , Cambridge , MA , USA
| | - Hendrik Neubert
- a Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc. , Andover , MA , USA
| | - Robert J Polzer
- d Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc. , Cambridge , MA , USA
| | - Denise M O'Hara
- a Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc. , Andover , MA , USA
| |
Collapse
|